Last €16.55 EUR
Change Today +0.97 / 6.22%
Volume 472.0
AB3A On Other Exchanges
As of 10:42 AM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

sarepta therapeutics inc (AB3A) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/24/13 - €43.75
52 Week Low
11/13/13 - €9.32
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

sarepta therapeutics inc (AB3A) Related Businessweek News

View More BusinessWeek News

sarepta therapeutics inc (AB3A) Details

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is Eteplirsen, an antisense PMO-based therapeutic in clinical development for the treatment of individuals with Duchenne muscular dystrophy. The company is also involved in developing treatments that are in clinical development include AVI-7288 for the treatment of Marburg virus and AVI-7100 for the treatment of influenza. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

146 Employees
Last Reported Date: 03/3/14
Founded in 1980

sarepta therapeutics inc (AB3A) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $580.0K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $457.2K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $377.7K
Senior Vice President, General Counsel and Co...
Total Annual Compensation: $376.9K
Senior Vice President of Technical Operations
Total Annual Compensation: $320.5K
Compensation as of Fiscal Year 2013.

sarepta therapeutics inc (AB3A) Key Developments

Sarepta Therapeutics Reports Long-Term Outcomes Through 144 Weeks from Phase IIb Study of Eteplirsen in Duchenne Muscular Dystrophy

Sarepta Therapeutics, Inc. announced data through Week 144 from Study 202, a Phase IIb open-label extension study of eteplirsen in patients with Duchenne muscular dystrophy (DMD). After nearly three years of follow up, results on the 6-minute walk test (6MWT) showed a decline in walking ability at a rate slower than would be expected based on available DMD natural history data. In addition, a continued stabilization of respiratory muscle function was observed, as assessed by pulmonary function tests. As previously reported, Study 202 met its primary endpoint of increased novel dystrophin as assessed by muscle biopsy at Week 48 and is now in the long-term extension phase in which patients continue to be followed for safety and clinical outcomes. At Week 144, patients in the 30 mg/kg and 50 mg/kg eteplirsen cohorts who were able to perform the 6MWT (modified Intent-to-Treat or mITT population; n=6) experienced a decline of 33.2 meters, or about 8.5%, from baseline in walking ability. A statistically significant treatment benefit of 75.1 meters (p<=0.004) was observed for the mITT population compared with the placebo/delayed-treatment cohort (n=4), which initiated treatment at Week 25 following 24 weeks of placebo. After experiencing a substantial decline of 68.4 meters from baseline to Week 36, the placebo/delayed-treatment cohort demonstrated a decline of 39.0 meters in walking ability from Week 36 through Week 144, the period from which meaningful levels of dystrophin were likely produced. These analyses were based on the maximum 6MWT score when the test was performed on two consecutive days. Through 144 weeks, eteplirsen was well tolerated and there were no reported clinically significant treatment-related adverse events and no treatment-related serious adverse events. In addition, there were no treatment-related hospitalizations or discontinuations. Patients performed two 6MWT evaluations on consecutive days at time points coinciding with a muscle biopsy procedure at baseline and Weeks 12, 24 and 48. Two 6MWT evaluations were also performed at Weeks 120 and 144, and will be performed at all future functional assessment visits. All other evaluations were a single 6MWT. The pre-specified primary analysis included the maximum distance walked at those clinic visits where repeated tests were taken. Other analyses of the repeated 6MWT results assessed mean, minimum, and Day 1 (first measure) scores. Results from these additional 6MWT analyses confirm the data observations in the primary analysis.

Sarepta Therapeutics, Inc. Presents at JMP Securities Healthcare Conference, Jun-24-2014 03:30 PM

Sarepta Therapeutics, Inc. Presents at JMP Securities Healthcare Conference, Jun-24-2014 03:30 PM. Venue: The Westin New York Grand Central, 212 East 42nd Street, New York, NY 10017, United States. Speakers: Christopher Nishan Garabedian, Chief Executive Officer, President and Director.

Sarepta Therapeutics, Inc. Presents at Boston CEO Conference, Jun-04-2014

Sarepta Therapeutics, Inc. Presents at Boston CEO Conference, Jun-04-2014. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, Massachusetts, United States. Presentation Date & Speakers: Jun-04-2014, Arthur M. Krieg, Chief Scientific Officer and Senior Vice President, Christopher Nishan Garabedian, Chief Executive Officer, President and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AB3A:GR €16.55 EUR +0.97

AB3A Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,354 GBp +8.50
Baxter International Inc $76.59 USD -0.16
Gilead Sciences Inc $88.73 USD -0.21
Hemispherx Biopharma Inc $0.30 USD +0.0072
SciClone Pharmaceuticals Inc $5.10 USD +0.06
View Industry Companies

Industry Analysis


Industry Average

Valuation AB3A Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 52.5x
Price/Book 3.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 42.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAREPTA THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at